Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort

Abstract Background & aims Despite its high prevalence in the western world metabolic dysfunction-associated steatotic liver disease (MASLD) does not benefit from targeted pharmacological therapy. We measured healthcare utilisation and identified factors associated with high-cost MASLD patients...

Full description

Bibliographic Details

Published in:	Clinical Diabetes and Endocrinology
Main Authors:	Arnaud Nze Ossima, Angélique Brzustowski, Valérie Paradis, Bernard Van Beers, Catherine Postic, Cédric Laouénan, Stanislas Pol, Laurent Castéra, Jean-François Gautier, Sebastien Czernichow, Anais Vallet-Pichard, Etienne Larger, Lawrence Serfaty, Marie Zins, Dominique Valla, Isabelle Durand Zaleski
Format:	Article
Language:	English
Published:	BMC 2024-04-01
Subjects:	Healthcare costs MASLD, NAFLD Comorbidities CONSTANCES Claims data
Online Access:	https://doi.org/10.1186/s40842-023-00163-4